Cellebrite DI Ltd.CLBTReports Thu, Nov 12 · Third Quarter 2026
Information Technology · Software & Services · NASDAQ · Israel · cellebrite.com
Cellebrite DI Ltd., founded in 1999 and headquartered in Petah Tikva, Israel, provides a digital intelligence platform for legally sanctioned investigations, offering software used by law enforcement agencies, defense and intelligence organizations, and enterprises to collect, review and manage digital evidence. Its AI-powered software portfolio is used by more than 7,000 organizations worldwide.
Key ratios
Operating cash flow growth
20.7%TTM
2025
31.3%2024
29.5%2023
396.0%
FCF / Sales
32.0%TTM
2025
33.7%2024
30.8%2023
29.8%
Net margin
14.5%TTM
2025
16.5%2024
-70.5%2023
-25.0%
ROA
4.8%TTM
2025
5.1%2024
5.8%2023
4.4%
ROE
19.1%2025
2024
-152.9%2023
-150.1%
Revenue growth
18.4%TTM
2025
18.6%2024
23.4%2023
20.1%
Recent news
Cellebrite to Report Third-Quarter 2026 Financial Results on November 12, 2026
Cellebrite Calls for 2027 JUSTYS Nominees, Premier Event Highlights Unsung Heroes Who Keep the World Safe
Cellebrite Expands Global Digital Community, 'The 101', for Digital Forensics and Investigative Professionals
Cellebrite CTO Chris Wade to Lead Cellebrite Labs, Sharpening Focus on Mobile Research
Cellebrite Initiates Plans to Redomicile in the United States
Cellebrite Announces Upcoming Investor Events in September
Cellebrite Guardian Completes IRAP Assessment: Achieves PROTECTED Level for Australian Government Agencies
Cellebrite Federal Solutions, Inc. (CFSI) Achieves U.S. Department of War's Advanced Cybersecurity Standard, Reinforcing Commitment to Secure Federal Operations
Cellebrite Brings Battlefield Intelligence to the Armed Forces with Launch of Portable Tactical Extraction Kit (C-TEK)
Cellebrite Genesis for Enterprise Now Generally Available, Regional Availability Expands to More Global Markets
Track CLBT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer